Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more
Regenxbio Inc (RGNX) - Total Liabilities
Latest total liabilities as of September 2025: $363.75 Million USD
Based on the latest financial reports, Regenxbio Inc (RGNX) has total liabilities worth $363.75 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Regenxbio Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Regenxbio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Regenxbio Inc Competitors by Total Liabilities
The table below lists competitors of Regenxbio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Finnair Oyj
PINK:FNNNF
|
USA | $3.05 Billion |
|
E2open Parent Holdings Inc
NYSE:ETWO
|
USA | $1.48 Billion |
|
Hwaxin Environmental Co. Ltd. A
SHE:301265
|
China | CN¥257.00 Million |
|
Potbelly Co
NASDAQ:PBPB
|
USA | $204.14 Million |
|
PT Berkah Beton Sadaya Tbk
OTCQX:BHBSY
|
USA | $88.66 Billion |
|
Vanda Pharmaceuticals Inc
NASDAQ:VNDA
|
USA | $161.76 Million |
|
Thinking Electronic Industrial Co Ltd
TW:2428
|
Taiwan | NT$5.07 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Regenxbio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regenxbio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regenxbio Inc (2013–2024)
The table below shows the annual total liabilities of Regenxbio Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $206.34 Million | -21.31% |
| 2023-12-31 | $262.23 Million | -17.30% |
| 2022-12-31 | $317.07 Million | -9.31% |
| 2021-12-31 | $349.61 Million | +5.81% |
| 2020-12-31 | $330.41 Million | +592.53% |
| 2019-12-31 | $47.71 Million | +36.45% |
| 2018-12-31 | $34.97 Million | +123.45% |
| 2017-12-31 | $15.65 Million | +42.32% |
| 2016-12-31 | $10.99 Million | +140.49% |
| 2015-12-31 | $4.57 Million | -50.24% |
| 2014-12-31 | $9.19 Million | +97.49% |
| 2013-12-31 | $4.65 Million | -- |